Clinical Trial Title
NCT05313165National Clinical Trial Number:
The PROMISE III Trial: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening IschemiaContact Information
Clinical Trial Protocol Description:
This study is for patients seeking treatment of chronic limb-threatening ischemia using the LimFlow System to provide additional information for creating an AV connection in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive approach to arterialize the pedal veins.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have a clinical diagnosis of chronic limb-threatening ischemia with ischemic ulceration or ischemic gangrene.
You will be excluded from the study if any of the following criteria apply to you:
- Have severe heart failure, severe kidney disease, and/or those with active infection.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.
Study Details
Clinical Trial Investigator
Sreekumar Madassery, MD
Contact Information
Karl Villanueva, MS, CCRP
Clinical Trial Location
Rush University Medical Center